Genes play a crucial role in controlling phenotypic variability of essentially all aspects of life, including susceptibility to disease. A better understanding of the genetic factors affecting the development and function of the central nervous system, especially the human brain, are of particular interest owing to the increasing prevalence of neurodegenerative disorders such as Alzheimer\'s disease (AD).

Investigators from the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) - a research project aimed at studying the rate of change of cognition, brain structure and function, and biomarkers in large collections of both cognitively healthy and impaired subjects - recently published data suggesting a possible connection between certain common genetic variants and brain volume in \~200 healthy older subjects \[[@B1]\]. Specifically, the authors tested the hypothesis of whether or not specific alleles in the gene encoding the fat mass and obesity-associated protein (*FTO*), located on chromosome 16q12.2, correlate with regional brain volumes as determined by magnetic resonance imaging.

This question arose because the same *FTO*alleles at - highly correlated - SNPs were previously found to show association with elevated body mass index (BMI), a commonly used surrogate measure of adiposity \[[@B2]-[@B5]\]. Elevated BMI itself has been reported to correlate with structural brain deficits - in particular, frontal, temporal, and subcortical atrophy \[[@B6]\] - but no study had previously assessed whether this correlation was driven by genetic variation in the *FTO*gene.

The new data from the ADNI group show that, indeed, the same common SNPs associated with BMI are also associated with a \~10% reduction in brain volume in the frontal and occipital lobes, while elevated BMI alone was associated with relatively broadly distributed brain atrophy in the frontal, temporal, parietal and occipital lobes \[[@B1]\]. As expected, the *FTO*association was highly correlated with the overall effect of BMI on brain volume, but the investigated *FTO*variants appeared to exert a small, but detectable, effect over and above what is explained by BMI alone. Interestingly, the *FTO*-related decrease in brain volume was not attributable to structural effects of microvascular damage in the white matter, as different regions of the brain were affected by both variables.

From the currently available data, it is impossible to judge which of the associated *FTO*sequence variants might confer the molecular effects underlying these genetic findings. The chromosomal region spanning the *FTO*gene is characterized by high inter-marker correlation (that is, linkage disequilibrium), making it difficult to determine which SNP is mainly driving the association. Interestingly, however, several of the polymorphisms determined either directly or indirectly by the ADNI group (that is, rs17817449, rs3751812 and rs1421085) were shown in a recent study to map to putative *in silico*functional elements \[[@B5]\] - although these observations still have to be confirmed *in vitro*. It has been previously suggested that, on a biochemical level, multiple processes could plausibly explain the role of FTO protein in weight regulation and obesity; for example, by controlling feeding behavior (possibly via neuronal circuits governing appetite) and/or energy expenditure (reviewed in \[[@B7]\]). Whether or not these same mechanisms are relevant for the potential effects of *FTO*on brain structure remains currently unclear.

As with any genetic association finding, the new results outlined above have some limitations and their potential relevance on brain function and dysfunction currently remains elusive. First, the investigated ADNI cohort was relatively small (*n*= 206), which increases the chance of sampling error and other biases, possibly leading to artifactual results. Small sample size also decreases power, which at least partially explains the rather modest degree of statistical support for most of the reported *FTO*findings. For instance, the study could not entirely exclude the possibility that the observed association between *FTO*and structural brain changes was merely a result of confounding with the - much more pronounced - BMI effects on brain volume, or a *bona fide*independent signal. Replication analyses in sufficiently powered and independent datasets will help to resolve this issue.

Second, *FTO*is not the only gene associated with BMI and obesity in humans. Several other loci - such as *MC4R*, *NPC1*, *MAF*, and *PTER*- have recently been identified to also play significant roles \[[@B8]\]. Assessing whether these genes also exert specific effects on brain structure would therefore be of interest. Conversely, it would be interesting to see whether other genes not related to obesity and BMI possibly show an even more pronounced association with brain atrophy than *FTO*; for example, after genome-wide screening.

Third, it will be interesting to see whether and how the reduction in brain volume in the frontal and occipital lobes exerted by *FTO*translates into altered cerebral function (for example, as measured using functional magnetic resonance imaging), and/or behavior in healthy subjects.

Finally, whether or not the reported *FTO*-brain connection has any relevance to neurodegenerative conditions, such as AD, remains to be seen. Only healthy older subjects have thus far been investigated, and the brain regions possibly affected by *FTO*(that is, the frontal and occipital lobes) are not typically struck early in the course of AD. A related study from the same ADNI investigators recently reported an association between elevated BMI and lower brain volume in subjects suffering from AD and mild cognitive impairment \[[@B9]\], although no results were reported on whether these effects were also correlated with *FTO*genotype. Furthermore, no study - including the several published genome-wide association studies \[[@B10]\] - has yet reported evidence for significant association between polymorphisms in *FTO*and AD risk or related phenotypes \[[@B11]\]. Based on the most recent ADNI data, however, this would seem a logical and promising hypothesis to test next.

In summary, the new ADNI data provide the first evidence for a possible link between one of the most important obesity genes and brain structure. Additional investigations are necessary to corroborate these findings, and to determine their relevance for normal brain function and disease.

Abbreviations
=============

AD: Alzheimer\'s disease; ADNI: Alzheimer\'s Disease Neuroimaging Initiative; BMI: body mass index; *FTO*: fat mass and obesity-associated protein; SNP: single nucleotide polymorphism.

Competing interests
===================

The authors declare that they have no competing interests.
